Awarded by the NIH’s Advanced Research Projects Agency for Health (ARPA-H), the contract helps the company develop SatioRx. This drug delivery device, compact and inexpensive, features disposable microneedle components for precise delivery. It remotely enables the delivery of a precise, metered dose of any liquid drug approved for transdermal delivery.
Under the contract, Boston-based Satio expects to leverage design features from its other patch-based devices. It also plans to utilize feasibility data from its manually operated transdermal delivery devices. Combining these, the company intends to develop a next-generation, remotely controllable device.
Get the full story at our sister site, Drug Delive…